Milestone Pharmaceuticals (MIST) Total Non-Current Liabilities (2020 - 2026)

Milestone Pharmaceuticals (MIST) has reported Total Non-Current Liabilities for 7 consecutive years, with $107.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Non-Current Liabilities rose 791.59% year-over-year to $107.8 million; the trailing twelve-month figure through Jun 2026 stood at $107.8 million (up 791.59% YoY), and the FY2025 full-year result was $16.1 million, up 74.03% from the prior year.
• Total Non-Current Liabilities grew to $107.8 million in Q2 2026 per MIST's latest filing, from $102.0 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $107.8 million in Q2 2026 and bottomed at -$48.3 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $8.7 million across 5 years, with a median of $9.0 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Total Non-Current Liabilities sank 65.42% in 2024, then surged 791.59% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at -$26.2 million in 2022, then jumped by 138.13% to $10.0 million in 2023, then fell by 7.2% to $9.3 million in 2024, then soared by 74.03% to $16.1 million in 2025, then jumped by 567.52% to $107.8 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $107.8 million, $102.0 million, and $16.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.